Principal
The aim of this study was to provide sufficient evidence to validate SLNB for pT3 BC, initially cN0 usN0, in case of up-front surgery. These cases can correspond to cT3 BC or cT2 BC with pT3 tumor on final pathology. The evidence analyzed on a large cohort of patients, distinguishing four size categories, was as follows: Comparison, according to categories sizes, of false negative (FN), negative predictive values (NPV), accuracy, axillary lymph node involvement rates, and evaluation of possible completion ALND omission rates according to categories sizes.
Secondaires
Institut Paoli Calmettes
232 Boulevard Sainte Marguerite
13273 Marseille Cedex 09
D’inclusion :
French cohort: all patients with up-front surgery for early breast cancer, included in a retrospective multicenter cohort from January 1999 to December 2022.
Patient’s inclusion criteria: invasive breast cancer, clinical stage cT0, cT1, cT2 or cT3, clinically negative axillary LN (cN0), SLNB alone or SLNB with cALND or ALND alone.
De non inclusion :
Patients were excuded if they had received neo-adjuvant chemotherapy and in case of clinically positive axillary LN (cN1).
Critère d’évaluation principal :
false negative (FN), negative predictive values (NPV), accuracy
Critères d’évaluation secondaires :
axillary lymph node involvement rates, and evaluation of possible completion ALND omission rates according to categories sizes.
Traitement de données mené dans l'intérêt public dans le domaine de la santé publique (article 6.1e et 9.2.j du Règlement (UE) n°2016/679)
institut paoli calmettes
Les données seront conservées pendant la durée légale en vigueur ou tant qu'elles présenteront un intérêt scientifique